A detailed history of Connecticut Wealth Management, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Connecticut Wealth Management, LLC holds 6,075 shares of HALO stock, worth $353,322. This represents 0.02% of its overall portfolio holdings.

Number of Shares
6,075
Previous 5,875 3.4%
Holding current value
$353,322
Previous $238,000 33.61%
% of portfolio
0.02%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$37.81 - $52.4 $7,562 - $10,480
200 Added 3.4%
6,075 $318,000
Q1 2024

May 01, 2024

BUY
$33.68 - $41.95 $2,290 - $2,852
68 Added 1.17%
5,875 $238,000
Q2 2023

Jul 25, 2023

BUY
$30.28 - $38.74 $175,835 - $224,963
5,807 New
5,807 $209,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.1B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Connecticut Wealth Management, LLC Portfolio

Follow Connecticut Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connecticut Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Connecticut Wealth Management, LLC with notifications on news.